Evidence map›Paper›PMID 30206903›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2018

Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study.

Natsu Otowa-Suematsu, Kazuhiko Sakaguchi, Tomoaki Nakamura, Kenta Hara, Minoru Kishi, Naoko Hashimoto, Kazuki Yokota, Hiroshi Yoshino, Yasuo Kuroki, Tomoko Nishiumi and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Natsu Otowa-SuematsuDivision of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Kazuhiko SakaguchiDivision of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan. kzhkskgc@med.kobe-u.ac.jp.ORCID http://orcid.org/0000-0003-1577-2401
Tomoaki NakamuraDivision of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Kenta HaraDepartment of Diabetes and Endocrine disease, Kita-harima Medical Center, Ono, Japan.
Minoru KishiDepartment of Internal Medicine, Nishiwaki Municipal Hospital, Nishiwaki, Japan.
Naoko HashimotoDepartment of Diabetes and Endocrinology, Hyogo Brain and Heart Center, Himeji, Japan.
Kazuki YokotaDepartment of Internal Medicine, Jinkeikai Ishii Hospital, Akashi, Japan.
Hiroshi YoshinoDepartment of Internal Medicine, Shinsuma General Hospital, Kobe, Japan.
Yasuo KurokiDepartment of Internal Medicine, Kobe Century Memorial Hospital, Kobe, Japan.
Tomoko NishiumiDepartment of Diabetes and Endocrinology, Kobe Rosai Hospital, Kobe, Japan.
Anna SouDivision of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Hisako KomadaDivision of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Yuko OkadaDivision of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Yushi HirotaDivision of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Yoshikazu TamoriDivision of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Wataru OgawaDivision of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Kobe University · JPHyogo Brain and Heart Center · JPHyogo Earthquake Memorial 21st Century Research Institute · JPKashiwa Municipal Hospital · JPKobe Rosai Hospital · JPTokyo-Kita Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWe comprehensively evaluated the effects of combination therapy with insulin glargine and the incretin-based drugs lixisenatide or vildagliptin in Japanese patients with type 2 diabetes.

methodsIn this 12-week, randomized, open-label, parallel-group, multicenter study (GLP-ONE Kobe), the incretin-based drug sitagliptin was randomly switched to lixisenatide (20 μg/day, n = 18) or vildagliptin (100 mg/day, n = 20) in patients with inadequate glycemic control despite combination therapy with insulin glargine and sitagliptin. The dose of insulin glargine was titrated after the switch to maintain fasting blood glucose at approximately 110 mg/dL. The primary end points of the study were the change in glycosylated hemoglobin (HbA

resultsThe change in HbA

conclusionThe combinations of basal insulin and either lixisenatide or vildagliptin have similar efficacies with regard to improvement of glycemic control.

trial registrationThis trial has been registered with UMIN (No. 000010769).

Indexed as

Insulin glargineLixisenatideVildagliptin

Identifiers

PMID30206903
PMCPMC6167300
OpenAlexW2890310681

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.